Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial.

@article{Pan2008ComparisonOV,
  title={Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial.},
  author={Chang-yu Pan and Wenying Yang and Jacqueline Barona and Markus Niggli and Pharis Mohideen and Yaxu Wang and James E Foley},
  journal={Diabetic medicine : a journal of the British Diabetic Association},
  year={2008},
  volume={25 4},
  pages={435-41}
}
AIMS To compare the efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor, vildagliptin, with the alpha glucosidase inhibitor, acarbose, in drug-naive patients with Type 2 diabetes. METHODS This multi-centre, randomized, double-blind, parallel-arm study compared the efficacy and tolerability of vildagliptin (100 mg daily, given as 50 mg twice daily, n = 441) and acarbose (up to 300 mg daily, given as three equally divided doses, n = 220) during 24-week treatment in drug-naive… CONTINUE READING
70 Citations
19 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 70 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 19 references

Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared to component monotherapy in patients with type 2 diabetes

  • S. Dejager
  • Diabetes Obes Metab
  • 2007

Similar Papers

Loading similar papers…